AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Centessa Pharmaceuticals' General Counsel Hussain Iqbal J buys and sells 6000 shares.
ByAinvest
Thursday, Jul 17, 2025 4:21 pm ET1min read
Centessa Pharmaceuticals plc (CNTA) has disclosed that General Counsel Hussain Iqbal J has recently made two transactions involving shares of the company. Firstly, he purchased 6,000 shares at a price of $5.84 per share on July 15, 2025. Secondly, he sold the same number of shares at a price of $14.93 per share on the same date.
Centessa Pharmaceuticals plc (CNTA), a clinical-stage pharmaceutical company, recently disclosed significant share transactions executed by its General Counsel, Hussain Iqbal J. On July 15, 2025, Iqbal purchased 6,000 shares at $5.84 per share, and subsequently sold the same number of shares at $14.93 per share on the same date [3].The transactions were reported under Rule 144 of the Securities Act of 1933, which governs the sale of securities by issuers and their affiliates. The sales were part of a Rule 10b5-1 trading plan, indicating a pre-established strategy for the sale of securities [3].
Centessa Pharmaceuticals plc is involved in the discovery, development, and delivery of medicines, with a focus on neurological and neurodegenerative disorders. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2 [1].
The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatment of neuropsychiatric disorders. Additionally, it offers LockBody, designed to selectively drive potent effector function activity, such as CD3, into the tumor microenvironment [1].
Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom. The company has a Relative Strength Rating (RSR) of 81, indicating strong technical performance [2].
References:
[1] https://finance.yahoo.com/quote/CNTA/
[2] https://www.investors.com/ibd-data-stories/stocks-to-watch-centessa-pharma-adr-sees-relative-strength-rating-jump-to-81/
[3] https://www.streetinsider.com/SEC+Filings/Form++144++++++++Centessa+Pharmaceuticals+++++++++++++++Filed+by%3A+HUSSAIN+IQBAL+J/25054580.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet